Risk of major bleeding during the at-risk period was also similar in rivaroxaban-treated and warfarin-treated participants ( 0.99 % versus 0.79 % per 30 days ; hazard ratio [ confidence interval ] = 1.26 [ 0.80-2 .00 ] ; P = 0.32 ) .